Lv1
20 积分 2023-11-15 加入
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
2天前
已关闭
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
2天前
已完结
LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)
2天前
已完结
非小细胞肺癌新辅助治疗疗效病理评估专家共识
20天前
已完结
[Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy]
20天前
已完结
WHO胸部肿瘤分类（第5版）中肺肿瘤部分解读
23天前
已完结
The Proposed 9th Edition TNM Classification of Lung Cancer
26天前
已完结
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
2个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
2个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
